文献速递精神分裂症与精神病性障碍

口服第二代抗精神病药长期疗效的系统综述与直接比较荟萃分析

Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons.
PubMed 文献 · World Psychiatry · 2019-01-01

该研究系统综述并荟萃分析了59项持续≥6个月的头对头随机试验(N=45,787),比较第二代抗精神病药(SGA)在精神分裂症及相关障碍维持治疗中的长期效果。主要结局为全因停药,结果显示不同SGA在疗效与耐受性上呈现不同模式,氯氮平、奥氮平和利培酮在全因停药上优于其他多种SGA,而喹硫平较差。长期风险获益需个体化权衡。

要点

  • 氯氮平、奥氮平、利培酮全因停药风险显著低于其他多种SGA,喹硫平则较差。
  • 奥氮平体重增加最差,利培酮和氨磺必利催乳素升高显著,氯氮平镇静更明显。
  • 长期SGA选择应基于个体化疗效与耐受性权衡。

核心结论

  • 不同SGA在长期疗效与耐受性上呈现不同模式,无一致优势药物。
  • 氯氮平、奥氮平和利培酮在全因停药上显著优于其他多种SGA,喹硫平较差。
  • 长期风险获益需根据具体药物特征个体化选择。

研究设计与样本

  • 系统综述与荟萃分析,纳入59项持续≥6个月的头对头随机对照试验,共45,787例精神分裂症及相关障碍患者。
  • 研究平均持续47.4±32.1周(范围24-186周),采用随机效应模型计算合并风险比和标准化均数差。

主要发现

  • 全因停药:氯氮平、奥氮平和利培酮显著优于其他多种SGA(p<0.05),喹硫平劣于其他多种SGA。
  • 精神病理学:氯氮平和奥氮平优于其他多种SGA,喹硫平和齐拉西酮劣于其他多种SGA。
  • 不可耐受相关停药:利培酮优于其他多种SGA,氯氮平劣于其他多种SGA。
  • 体重增加:奥氮平差于所有其他对照的非氯氮平SGA,利培酮显著差于其他多种SGA。
  • 催乳素升高:利培酮和氨磺必利显著差于其他多种SGA;帕金森综合征奥氮平优于利培酮,静坐不能无显著差异;镇静嗜睡氯氮平和喹硫平显著差于某些其他SGA。

关键数值与推荐

  • 全因停药、精神病理学、不可耐受相关停药、体重增加、催乳素升高、帕金森综合征、镇静嗜睡等结局的合并风险比和标准化均数差见原文。
  • 原文未报告具体阈值或推荐条款。

临床怎么用

  • 长期维持治疗选择SGA时需兼顾疗效与耐受性,如氯氮平疗效较好但需关注镇静和不可耐受停药风险。
  • 奥氮平需重点监测体重增加,利培酮和氨磺必利需监测催乳素升高。

局限性

  • 其他疗效结局数据稀疏,部分比较证据有限。
  • 研究持续时间异质性较大(24-186周),可能影响合并结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Second-generation antipsychotics (SGAs) are recommended for maintenance treatment in schizophrenia. However, comparative long-term effectiveness among SGAs is unclear. Here we provide a systematic review and meta-analysis of randomized trials lasting ≥⃒6 months comparing SGAs head-to-head in schizophrenia and related disorders. The primary outcome was all-cause discontinuation. Secondary outcomes included efficacy and tolerability, i.e., psychopathology, inefficacy-related and intolerability-related discontinuation, relapse, hospitalization, remission, functioning, quality of life, and adverse events. Pooled risk ratio and standardized mean difference were calculated using random-effects models. Across 59 studies (N=45,787), lasting 47.4±32.1 weeks (range 24-186), no consistent superiority of any SGA emerged across efficacy and tolerability outcomes. Regarding all-cause discontinuation, clozapine, olanzapine and risperidone were significantly (p<0.05) superior to several other SGAs, while quetiapine was inferior to several other SGAs. As to psychopathology, clozapine and olanzapine were superior to several other SGAs, while quetiapine and ziprasidone were inferior to several other SGAs. Data for other efficacy outcomes were sparse. Regarding intolerability-related discontinuation, risperidone was superior and clozapine was inferior to several other SGAs. Concerning weight gain, olanzapine was worse than all other compared non-clozapine SGAs, and risperidone was significantly worse than several other SGAs. As to prolactin increase, risperidone and amisulpride were significantly worse than several other SGAs. Regarding parkinsonism, olanzapine was superior to risperidone, without significant differences pertaining to akathisia. Concerning sedation and somnolence, clozapine and quetiapine were significantly worse than some other SGAs. In summary, different long-term SGA efficacy and tolerability patterns emerged. The long-term risk-benefit profiles of specific SGAs need to be tailored to individual patients to optimize maintenance treatment outcomes.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kishimoto T, Hagi K, Nitta M, et al. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019. PMID: 31059621. doi:10.1002/wps.20632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。